Compass Pathways' Phase IIb psilocybin trial shows reduced depression symptoms
UK biotech Compass Pathways revealed this morning that they reached the primary endpoint in a Phase IIb clinical trial of psilocybin therapy.
In the randomized, controlled and double-blind trial, investigators looked at a single dose of Compass’s investigational psilocybin therapy COMP360 for treatment-resistant depression in 233 patients, given alongside psychological support. The trial, which had all patients stopping antidepressants before participating, compared two active doses of COMP360, 25mg and 10mg, against a comparator 1mg dose.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.